Your search for esrd returned 16 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Post remove
Older than 2 years remove
MPR First Report remove

Your search for esrd returned 16 results

Sort Results:

Relevant Recent
American College of Cardiology 2011

Lipid Management in Special Populations

Statins are the most widely prescribed agents in the world. While muscle-related adverse effects associated with statins are well known, accurately quantifying their incidence to guide clinicians with respect to lipid management can be difficult, said Richard H. Karas, MD, PhD, Tufts Medical Center, Boston, at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
ACR/ARHP Annual Meeting 2013

CZP + MTX Demonstrate Favorable Long-Term Efficacy in Active RA

At the 2013 ACR/ARHP Annual Meeting, study authors presented that patients with active rheumatoid arthritis (RA) despite methotrexate (MTX), certolizumab pegol (CZP) + MTX maintained reduction in signs and symptoms through 5 years.
ACR/ARHP Annual Meeting 2013

Twice-Daily Tofacitinib Shows Sustained Efficacy Over 5 Years in RA

Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension studies for patients with rheumatoid arthritis, as presented at the 2013 ACR/ARHP Annual Meeting.
ACR/ARHP Annual Meeting 2015

Tofacitinib Efficacy Unaffected by Methotrexate Dose in RA

Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and "appeared similar regardless of methotrexate dose" in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.